4 Penny Stocks That You Might Want to Pay Attention To
As we inch further into March, many penny stocks are illustrating their potential. In only the past few days, we have seen the market turn from neutral to relatively bullish. This bullish rally is playing out through many different areas of the stock market. It includes everything from tech and energy penny stocks to big-name blue-chip companies.
While it’s difficult to identify one main contributing factor, it seems as though there are a few things at play. During the past few days, investors have begun to feel more confident with the pandemic’s long-term outcome. This includes the optimism stemming from vaccine distribution at a higher rate than ever before.
These factors combine to show that the economy in the U.S. could be bouncing back toward normalcy. We also have to consider that the economy was on track for a stellar year before the pandemic occurred. Because of this, many investors are hopeful that we can move back toward a broadly bullish market.
With this in mind, there are plenty of penny stocks that are benefitting from the bullish rally. While fundamentals are always key, investors should also consider the speculative events that are occurring. All things considered, here are four penny stocks to watch that have already started turning heads before Thursday’s opening bell.
Penny Stocks to Watch
- BioSig Technologies Inc. (NASDAQ: BSGM)
- Nova Lifestyle Inc. (NASDAQ: NVFY)
- OpGen Inc. (NASDAQ: OPGN)
- Siebert Financial Corp. (NASDAQ: SIEB)
BioSig Technologies Inc.
Within the biotech industry, there are plenty of penny stocks trying to make a name for themselves. This includes BioSig Technologies, which is a producer of medical technology. Its flagship product, known as the PURE EP system, could change how cardiovascular health is diagnosed. This device uses a signal known as electrophysiology to diagnose and treat heart irregularities in patients.
It’s always great for investors to find a company working on a novel solution when it comes to biotech. BioSig recently announced that it has plans to develop a large portfolio of neurostimulation products. By 2024, estimates show this area of biotech to be worth as much as $12.2 billion.
A week ago, the company was awarded a U.S. patent claim to its NeuroClear subsidiary. NeuroClear has reportedly licensed an electroporation methodology system from the Mayo Foundation for Medical Education and Research. The goal is to use this technology to develop its N-SENSE platform further. CEO Kenneth Londoner stated that “Our first neurostimulation product aims to address a vast market of neurological conditions through a proprietary sensing design and algorithms tailored to specific applications. Electroporation is a novel technique that has significantly advanced cancer treatments and has shown promise in treating cardiovascular disease.”
Nova Lifestyle Inc.
Nova is a designer and distributor of modern lifestyle furniture. This includes everything from sofas and dining room furniture to office needs and more. It appeals to the higher-end market, with customers across the U.S., Europe, China, and more. Only a few weeks ago, the company announced the launch of its HealthLine platform in Malaysia.
This is to enhance the consumer experience by offering a reward program for its Malaysian customers. Tawny Lam, CEO of Nova, stated that “we believe membership-based HealthLine platforms and reward programs will provide health-conscious consumers with an added benefit that goes above and beyond just a healthy lifestyle.”
In the announcement, the company said it would disseminate a large range of products manufactured by 3H Korea Co Ltd. These are medical devices that can be used in the home to improve one’s lifestyle. This includes products that use far infrared rays to provide heat and alleviate pain in the body. While not much else has come out of the company in the past month or so, attention has come into NVFY stock on Wednesday. Will that continue until the end of the week?
OPGN is a penny stock that we’ve been covering for quite some time. A few days ago, the biotech company announced its Unyvero HPN Panel’s final study results for diagnosing bacterial infections in hospitalized Covid-19-related pneumonia cases. The study showed that its panel could be a highly reliable and rapid way to diagnose bacterial pathogens in the body.
The main problem that the company sees as an opportunity is the unnecessary prescription of antibiotics for those who are suffering from covid at the same time as a bacterial infection. The study states that “current estimates suggest that nearly 80% of the patients admitted in the ICU with Covid-19 receive antibiotics. It is most likely possible that the bacterial super-infections among Covid-19 patients admitted to critical care units are no longer due to the longer duration of stay in the ICU and mechanical ventilation, rather than the viral infection itself.”
A few days earlier, the company announced that it had received NMPA Approval for its Curetis Unyvero System in China. Oliver Schacht, CEO of OpGen, stated that “we are truly excited to see the Chinese regulators approve our Unyvero System based on the A50 Analyzer as a diagnostic instrument for the Chinese market. We have been working very closely with the NMPA and our partner BCB for several years towards this key milestone.”
Siebert Financial Corp.
Siebert Financial Corp. is another penny stock that you may not have heard of. But after nearly doubling in value on March 10th, you may want to put it on your radar. This massive rise in value is a reflection of the company’s full-year 2020 results. In the results, it posted sales of $54.9 million, which is much more than the $28.6 million it posted during the same period last year. Additionally, the company posted an operating income of $1.3 million for the full year.
This represents an EPS of $0.10. Gloria Gebbia, the controlling shareholder and board member of Siebert, stated that “we are excited to see our strategic acquisitions and new revenue streams driving growth for our company. Regarding the Covid-19 crisis, we have reopened our branch offices while ensuring compliance with federal, state, and local laws as well as health and safety guidelines.”
During the quarter, Siebert also posted quarterly revenue of $1.5 million. This is a record for the company and represents an increase of more than 500% over the fourth quarter of 2019. In January, Siebert announced a sizable equity interest in OpenHand, a brokerage platform that allows zero-commission equity and options transactions. For some context, Siebert is a retail brokerage business working through several different subsidiaries. Within its overall business are Siebert AdvisorNXT Inc, WPS Prime Services, and three other subsidiaries. All of these work to make up its vast portfolio of brokerage services for its customers.
As a finance company, Siebert has a lot of exposure to the markets’ ups and downs. But, a focus on industry stocks could have SIEB on the watch list this week.